Exploring Easd 2017 Poster 671
Let's dive into the details surrounding Easd 2017 Poster 671.
- Gill Hamilton Characteristics of patients with type 2 diabetes initiating canagliflozin compared with other treatment regimens in the ...
- Liana Billings Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: ...
- Yoshimasa Aso Effect of insulin degludec versus insulin glargine on glycaemic control and daily fasting blood glucose variability ...
- Geoffrey Rezvani Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on ...
- Francesca Porcellati More physiological circulating insulin and modulation of hepatic glucose production with insulin Glargine ...
In-Depth Information on Easd 2017 Poster 671
Luigi Meneghini Converting to IDegLira is efficacious regardless of pre-trial insulin dose in patients with type 2 diabetes ... Carol Wysham Insulin degludec (IDeg) shows consistent risk reductions across hypoglycaemia definitions vs insulin glargine ... Bernd Schultes Real-world use of IDegLira is effective at moderate doses in patients with type 2 diabetes across all baseline ... Alistair Lumb Effect of insulin degludec on HbA1c, weight and hypoglycaemia: data from the Association of British Clinical ...
This interview with Marc Evans from University Hospital Llandough, Cardiff, UK discusses Treating Diabetes in Heart Failure ...
That wraps up our extensive overview of Easd 2017 Poster 671.